BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/6/2020 7:54:48 AM | Browse: 889 | Download: 1390
 |
Received |
|
2019-12-17 14:55 |
|
Peer-Review Started |
|
2019-12-17 14:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-02-20 23:11 |
|
Revised |
|
2020-03-05 08:52 |
|
Second Decision |
|
2020-03-09 15:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-03-09 17:43 |
|
Articles in Press |
|
2020-03-09 17:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-03-21 04:08 |
|
Typeset the Manuscript |
|
2020-04-03 11:58 |
|
Publish the Manuscript Online |
|
2020-04-06 07:54 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Hui Guo, Yuan-Yuan Wang, Jiang-Wei Zhang, Pei-Min Liu, Yan-Jun Hao and Hai-Rui Duan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81872032 |
|
| Corresponding Author |
Jun-Hui Guo, MAMS, MPhil, Chief Doctor, Department of Oncology, The Second Affiliated Hospital of Henan University of Chinese Medicine, Henan Province Hospital of TCM, No. 6 Dongfeng Road, Zhengzhou 450002, Henan Province, China. gjunhui2008@163.com |
| Key Words |
Esophageal squamous cell carcinoma; Cervical adenocarcinoma; Brain micrometastases; Apatinib; Tyrosine kinase inhibitor; Vascular endothelial growth factor |
| Core Tip |
Brain metastases are the most common intracranial tumor, the average survival time of patients after symptomatic treatment with chemotherapy, radiotherapy and hormonal drugs is less than 1 year. We report two patients with multiple micrometastases in the brain after failure of second-line treatment, and both had extracerebral metastases. By taking apatinib, the intracerebral lesions disappeared and the extracerebral lesions were partially alleviated. Both patients received progression-free survival for more than 12 mo and are still stable. Apatinib, a small-molecule oral inhibitor with anti-angiogenic function, may be an option for brain metastases. |
| Publish Date |
2020-04-06 07:54 |
| Citation |
Guo JH, Wang YY, Zhang JW, Liu PM, Hao YJ, Duan HR. Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. World J Clin Cases 2020; 8(7): 1326-1336 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i7/1326.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i7.1326 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
